As an alternative modality to conventional radiotherapy, electrons with energies above 50 MeV penetrate deeply into tissue, where the dose can be absorbed within a tumour volume with a relatively small penumbra. We investigate the physical properties of VHEEs and review the state-of-the-art in treatment planning and dosimetry. We discuss the advantages of using a laser wakefield accelerator (LWFA) and present the characteristic features of the electron bunch produced by the LWFA and compare them with that from a conventional linear accelerator.
INTRODUCTION
Intensity-modulated radiotherapy (IMRT) using X-rays between 4 and 22 MeV is currently the most flexible method of delivering a high radiation dose to a target volume while simultaneously protecting adjacent sensitive tissue. IMRT spreads the dose over a large volume of healthy tissue while concentrating maximum dose within the tumour volume. However, its efficacy is still questioned by some 1 and it carries an increased risk of radiation induced malignancy. 2, 3 In contrast, advanced radiotherapy modalities such as proton and ion beam therapies have been shown to be effective because of the combination of their high penetration, favourable dose distributions within tissue, and increased radiobiological effectiveness. However, their cost is currently considered too high for wide availability because large infrastructures are required to transport beams to the patient. 4 Recent investigations have shown that electrons with increased energy (up to 50 MeV) feature favourable dose distributions, particularly in combination with photon beams. [5] [6] [7] Very high energy electron (VHEE) therapy using electron beams up to 250 MeV was first considered by DesRosiers et al. 8, 9 as a viable and cost-effective alternative to intensity-modulated radiation therapy (IMRT) with photon and proton beams. Theoretical studies, based on the Monte Carlo (MC) methods, have demonstrated that VHEEs provide an implicit tool for scanning deep-seated lesions. The dosimetric characterisation of VHEE beams has already been performed in previous work. [10] [11] [12] [13] [14] [15] These studies conclude that main secondary products of the VHEE interactions with water molecules, neutrons and protons, should not significantly affect equivalent doses in comparison with photon treatments.
The treatment planning comparison studies provide necessary information for introduction of new radiotherapy modalities into clinical practice. Monte Carlo-aided simulations [16] [17] [18] [19] [20] [21] were carried out towards assessment of treatment planning with VHEEs. The lower ratio of total dose to the target dose, higher dose rates (Gy/s) and therefore better conformity to the tumour volume and tissue sparing, comparable to traditional photon therapy with energies 6 and 16 MV, have been investigated and reported. Utilising the voxel-PENELOPE engine code as a preliminary treatment planning system (TPS) for very high energy electron therapy (VHEET) has been recently proposed. 15, 20 This is a significant move towards building a tool allowing further comprehensive studies for designing and planning of future VHEET systems. Yeboah and Sandison, following the current trends in radiotherapy quantified the performances of treatment plans using VHEEs versus photon and proton therapy. They have shown that the probability of complication-free tumour control for clinically relevant treatment plans decreases in the following order; intensity-modulated proton therapy (IMPT), VHEET and intensity-modulated X-ray therapy (IMXT), respectively. 22 The feasibility of using intensity modulated VHEET and VHEE Pencil Beam Scanning (PBS) have been explored in more detail. 15, 23 The present research on VHEEs aims to investigate technical features, treatment quality, delivery and manipulation of VHEEs. [24] [25] [26] [27] To improve dose distribution and examine the radiobiological effectiveness (RBE) of VHEEs have yet to be explored. , due to the rapid increase to a peak dose in the shallow depths, produce low surface dose causing less damage to the skin. In IMRT the number of beam portals arranged in several angles around the patient, is used to create a dose plateau deep inside the tissue and a sharp dose contrast at the tumour edge (1b).
CURRENT RADIOTHERAPY MODALITIES VS. VHEES
Clinical electron beams with energies in the range of 4-25 MeV (1c) have finite penetration range in tissue, after which the dose falls off rapidly. As such, this radiation modality is suitable for treatment of superficial lesions, and rarely in intraoperative radiotherapy to provide a boost to the tumour bed. Sub-cutaneous and visceral cancers are treated with electrons in this energy range in combination with megavoltage photon beams.
28
Protons and heavy ions (150 -300 MeV) deposit most of their energy into a narrow region known as the Bragg peak (1d). Therefore, these beams have tremendous advantage over X-rays allowing precise localisation of dose in a tumour. The uniform dose region, in the longitudinal direction, referred to as Spread-out-Bragg Peak (SOBP) (1e), can be achieved by integrating the planar dose distributions created by altering the initial proton energy at the accelerator source. A high level of entrance dose results from the superposition of several narrow mono-energetic pencil-shaped beams during intensity modulated proton therapy (IMPT).
The depth of maximum dose deposited by 150 MeV electron beams (1f) already exceeds the depth of most deep-seated tumours (>10 cm). For depths ≤ 5 cm VHEEs have been proven to exhibit penumbrae comparable to photons, 9 and more uniform dose distribution at larger depths. VHEEs do not exhibit significant perturbations when propagating through tissues of varying densities, unlike photons 9 and protons, 29 which abruptly scatter and dissipate the dose within surrounding tissue. The dose distribution can be shaped by using non-overlapping multiple beams similar to those found in the IMRT scheme. For particle beams the probability of scattering events increases with depth. Electrons transfer most of their energy to tissue at the end of their range similar to protons. However the most intense scattering, at the Bragg peak, takes place beyond the patient since VHEEs exit the tissue before they terminate propagation.
LASER PLASMA VS. CONVENTIONAL ACCELERATORS
Over the past decade, significant efforts have been made to develop complex beam geometries and control the particle and radiation beams transport employing superconducting magnets. [30] [31] [32] Additionally, this technology enables to produce more compact sources. However, the size of hadron therapy centres still remains large because of immense gantries required to transport the beam, long beamlines and extensive shielding. All of these translate into high construction and running costs. For instance, the price of building proton centre is 40 times higher than for LINAC X-ray facility.
33 Therefore access to hadron therapy is limited what stimulates a search for more compact types of accelerators and alternative radiation modalities. Very high energy electron therapy, proposed by DesRosiers et al. 8 has a potential of becoming new radiation treatment method due to dosimetric advantages over conventional X-rays. However, the high cost and size of LINAC-based VHEE accelerators has thwarted progress in developing the VHEE modality. In 1979 Tajima and Dawson 34 introduced the concept of Laser Wakefield Acceleration (LWFA). This technology offers a much more compact accelerator footprint, requiring sufficient laser technology as the main driver. The development of table-top laser systems allows the true potential of LWFA to be explored. In 2004, three independent research groups 35-37 used the LWFA concept to demonstrate a new type of accelerator based on laser-driven plasma waves. In laser-plasma wakefield accelerators (LWFAs) background plasma electrons are trapped in the LWFA plasma bubble "structure" and get accelerated coherently to extremely high energies over several millimetres. High quality, mono-energetic, ultra-short duration, high peak current electron bunches are produced simply by placing a supersonic hydrogen or helium gas jet at the focus of an ultra-short pulse terawatt (TW) laser beam. 
Typically 10
18 -10 19 electrons/cm 3 provide the space-charge fields of plasma of the order of 100 GV/m, which is roughly 1000 times higher than in cavities of conventional accelerators. 39 This allows to reduce the size of a 100-200 MeV accelerator from 10s of metres to just 1-2 mm exceeding currently existing energy limits.
40, 41
Conventional S-band LINACs typically produce electrons with few microsecond duration macro-pulses formed of ≈3 GHz micro-pulse trains of 10-35 ps duration and ≈30 pC charge. In contrast, LWFA VHEE electrons have bunch durations of around 1 femtosecond (10 −15 s) at source, charges of ≈10 pC, and δE/E≈1-10% energy spread. 42 They currently operate at a repetition rate of up to 10 Hz, but progress is being made to extend the rates to 1 kHz (e.g. by using Coherent Amplifying Network (CAN) laser). Shortly after first experimental demonstration of the LWFA, these sources were considered as a potential way of producing VHEEs for radiotherapy. 10 Simulations of 170 MeV LWFA electrons were used to investigate an inverse treatment planning system for intensity-modulated treatments, which showed better target coverage than 6 MV IMXT. 19 An example of an LWFA source used for radiobiology studies is the Advanced Laser-Plasma High-energy Accelerators towards x-ray (ALPHA-X) project at the University of Strathclyde 14 . The accelerator beamline is part of the various dedicated beamlines available across three shielded areas at the Scottish Centre for the Application of Plasma-based Accelerators (SCAPA). This state-of-the-art centre offers a suite of high peak-power laser systems to drive accelerators towards unique applications. SCAPA offers 40 TW and 350 TW peak-power laser systems across a range of accelerator type and technologies. SCAPA 40 TW laser system delivers a laser pulse of 35 fs pulse duration with a central wavelength of 800 nm at repetition rate up to 10 Hz and energy of 900 mJ on target and has already been used for dosimetry measurements of VHEEs.
11, 13 The ALPHA-X beam line is shown in Figure 3 . The SCAPA 40 TW laser beam coming directly from the compressor is focused at the entrance of a gas-jet by a spherical mirror (with focal length 80 cm). The laser is focused to a focal spot diameter of 40 µm (1/e 2 diameter) into a supersonic helium gas jet. The aberration-free focal spot can be achieved by proper alignment of the f/18 spherical mirror. When the laser beam interacts with plasma, electron beams with energy of at least 100 MeV and δE/E≈1% energy spread are produced. A setup of three miniature permanent magnet quadrupole (PMQ) lenses, are available preventing electron beam blow-up over long drift propagation as they pass through Lanex screens, used to monitor the transverse beam profile. The energy spectrum is measured by a spectrometer co-aligned with the beam line axis. Multiple Lanex screens imaged by high-resolution charge-coupled device (CCD) cameras are available to monitor the electron beam profile/pointing along the linear beamline. The very short duration and high charge density of electron bunches produced by ALPHA-X (in the range of 5-10 pC) lead to very high energy beams ideally suited to VHEE studies.
DOSE RATES AND TREATMENT TIME
Several factors have a strong impact on tumour cell kill and tumour response outcome. Among these, dose rate and overall treatment time are pertinent and depend on accelerator capabilities. The dose-rate range in external radiotherapy extends from about 1.8 Gy/hr to several Gy/min and usually varies with the acceleration type, source to surface distance (SSD), energy and geometry. Commercial medical LINACs operate within dose rate up to 6 Gy/min while cyclotrons for proton therapy deliver typically 2 Gy in less than 1 min. Patient comfort during the treatment and treatment accuracy are directly related with radiation treatment time. Treatment duration is established based on accelerator capabilities (dose rate regime), tolerance dose and recurrence time of normal cells. A number of studies have shown that early-stage cancer treated with a shorter and more intense radiation (e.g. accelerated hypofractionated whole breast irradiation) results in fewer side effects than the traditional six-week course. [44] [45] [46] The ALPHA-X accelerator is capable to produce a bunch (shot) of electrons with a charge typically 10 pC carrying 6.25×10
7 particles corresponding to 0.07 cGy. For a 10 Hz laser system the number of shots to deliver 2 Gy to the target (water) at 15 cm depth is around 3000, this translates to approximately 5 minutes irradiation time and dose rates around 0.4 Gy/min. Therefore, efforts are being continued to increase the delivered charge of the produced electron bunches in order to increase dose rates. 47 Proton therapy accelerators, on the other hand, with a built-in gantry systems are currently capable of delivering at a rate of roughly 3000 Bragg peaks per minute (≈ 2 Gy), equivalent to 50 Hz, 48 this translates into delivery times per field of between a few seconds to 20-25 min. The arrangement of two opposite fields escalates the treatment time to 50 min.
RADIOBIOLOGY
Two mechanisms of cell kill are commonly identified path-ways in radiobiology: single and double DNA hit mechanisms. The former is associated to be responsible for sub-lethal DNA double-strand breaks (DSB) and thus chromosome aberration formation at the micrometre level, whereas the latter causes lethal damage by several chemical changes to DNA at the nanometre level. Normal tissue complication can result from the inactivation of stem cells by both mechanisms but tissue architecture or damage to vasculature could also play a role. In current clinical practice 1.8 -3 Gy fractions are administrated for 5 days a week, up to the prescribed dose to the tumour area. The optimal combination of adequate killing of tumour clonogens and the time given to normal cells for convalescence, fractionation scheme, is decided by oncologist based on specification of the clinical case. It has been shown that irradiation with low dose rates in many fractions results in reduced cell killing due to fast proliferation of the tumour cells and enzymatic repair of sub-lesions in the tumour. 49 The effects of dose-rates below the threshold at which micrometer-scale effects are still observable are studied based on the mechanism of DNA double strand breaks (DSBs), gene mutations, chromosomal aberrations and cell-cycle activation and apoptosis. The probability of killing the cell depend on the cell phase at the point when radiation is delivered. The cell is more radiosensitive in phases G2-phase and mitosis. In S phase, when DNA is being replicated, cells seem more able to repair DNA damage. However, the cell-cycle is a stochastic factor and depends upon the statistics of the number of cells found in the same phase.
In 1959 Bergonie and Tribondeau
50 proved that increased sensitivity to radiation is seen in populations of cells that are highly proliferative with rapid cell divisions and less differentiated (i.e. stem cells are more sensitive than mature somatic cells). Tumour cells usually divide faster than normal cells thus there are more sensitive to radiation. Poorly-differentiated carcinomas are the most aggressive tumours or cancers in their final stage. Due to uncontrolled proliferation some areas within tumour are isolated from blood vessels and become hypoxic (more resistant). To achieve uncomplicated local regional control of cancer different types of cells/tissue need to be treated with various dose rates resulting in improved treatment efficiency. The dose rates which impact the biological response can be established based on the existing mathematical models; tumour control probability (TCP) and normal tissue complication (NTCP). The former is a probability of killing tumour cells after a certain total dose is delivered, whereas the later is defined as the probability that a certain percentage of the patient population will incure unfavourable side effects at a particular dose. Current LWFA technology, in contrast to conventional accelerators, are able to vary in repetition scaling (up to 10 Hz) allowing alternating dose rate.
FUTURE OUTLINE
The LWFA accelerator is a promising and cost-effective alternative to produce VHEEs. Its compact size is dictated by the use of a non-ionising radiation source (laser light). Therefore, transport of the laser beam up to the accelerator head requires no additional shielding unlike in conventional accelerators. Furthermore, instead of traditional around 2-3 m long arrangement of RF cavities and bending magnets to accelerate and transport the beam, the gantry of a LWFA accelerator would contain laser optics for guiding the laser beam and the acceleration would take place in the plasma cell of less than mm 41 length mounted in the accelerator head. The conceptual scheme of the future accelerator was proposed by Nakajima et al. 51, 52 Additional advantages of the LWFA design is the possibility to be developed into a multimodal machine. Laser-plasma electron bunches can be used to produce X-rays and protons through laser-solid target interactions (with the target placed in the accelerator head). However, production of protons, using laser-plasma technology, is currently very limited due to low efficiency of energy conversion (around 1%) and, therefore, reduced beam quality.
The laser transport allows the optical geometry to be adapted to transport the laser to various fixed accelerators around the patient (multiple beams) and many treatment rooms (see Figure 4) . A new dedicated treatment room B treatment room C beamline at SCAPA will distribute the LWFA produced radiation in a vertical orientation, as opposed to the LWFA community standard of a horizontal accelerator. Using this layout pioneering radiotherapy cell studies can be performed in a traditional patient style layout. In addition, SCAPA laser system and current LWFA technologies are able to vary in repetition scaling (up to 10 Hz) allowing further investigation towards the future charge/dose rate modulation VHEET. 
CONCLUSIONS
The ability to produce extremely short electron bunch durations from LWFA can provide a more effective way of killing cancer cells and reducing treatment time. The key challenges remain to identify the biological mechanisms following exposure to LWFA VHEE beams to understand their dose and dose-rate responsiveness and manifest clinically increased tumour control. The designed radiobiological models can be used to estimate the dose rates which impact the biological response. Based on the existing knowledge VHEEs administrated in the similar way to IMRT can provide similar tumour conformity and lower entrance dose in treatment of deep-seated tumours.
A combination of compacted, cost-effective technology and favourable dosimetric properties of VHEEs is a promising alternative which offers multiple options to design high precision, compact and cost-effective radiotherapy modality. Advanced optical technology allows to share one laser beam between multiple rooms in addition to providing an easy and stable guiding system with no shielding required. The electron beams can be delivered in a portable mode from robotic arm (similar to Cyber Knife) or gantry (similar to proton therapy but in more compact way). 51, 52 We propose a novel solution, the multiaccelerator arrangement in a single treatment room, which can allow many beams to be delivered at the same time. This mode could significantly reduce the radiation time and treatment uncertainties compared to X-ray therapy. The additional advantages of LWFA over conventional LINACs are the capability to produce different types of radiation (electrons, X-rays and protons) and control beam parameters from the source by changing parameters of the laser and the gas.
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